<unk> <unk> , also known as metabolic (dysfunction) associated<unk>  liver disease <unk> , is excessive fat build-up in the liver without another clear cause such as alcohol use. There are two types;<unk> -alcoholic<unk>  liver <unk>  and<unk> -alcoholic steatohepatitis (NASH), with the latter also including liver inflammation.<unk>  is less dangerous than NASH and usually does not progress to NASH or liver cirrhosis. When<unk>  does progress to NASH, it may eventually lead to complications such as cirrhosis, liver cancer, liver failure, or cardiovascular disease. Obesity and type 2 diabetes are strong risk factors for<unk> . Other risks include being overweight, metabolic syndrome (defined as at least three of the five following medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum HDL cholesterol), a diet high in fructose, and older age.<unk>  and alcoholic liver disease are types of<unk>  liver disease. Obtaining a sample of the liver after excluding other potential causes of<unk>  liver can confirm the diagnosis. Treatment for<unk>  is weight loss by dietary changes and exercise. There is tentative evidence for pioglitazone and vitamin E; bariatric surgery can improve or resolve severe cases. Those with NASH have a 2.6% increased risk of dying per year.<unk>  is the most common liver disorder worldwide and is present in approximately 25% of the world's population. It is also very common in developed nations, such as the United States, and affected about 75 to 100 million Americans in 2017. Over 90% of obese, 60% of diabetic, and up to 20% normal-weight people develop it.<unk>  is the leading cause of chronic liver disease and the second most common reason for liver transplantation in the US and Europe as of 2017.<unk>  affects about 20 to 25% of people in Europe. In the United States, estimates suggest between 30 and 40% of adults have<unk> , and about 3 to 12% of adults have NASH. The annual economic burden was approximately US$103 billion in the US in 2016.
Non-alcoholic fatty liver disease
Metabolic syndrome
Alcoholic liver disease
Alcoholic hepatitis
Fatty liver disease
Autoimmune hepatitis
Viral hepatitis
Polycystic liver disease